Editorial Board ::: Current Molecular Pharmacology

ISSN: 1874-4702 (Online)
ISSN: 1874-4672 (Print)


Volume 10, 4 Issues, 2017


Download PDF Flyer




Current Molecular Pharmacology

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michael Kahn
University of Southern California
1450 Biggy Street
Los Angeles, NRT 4501, CA 90033
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Michael Kahn
University of Southern California
1450 Biggy Street
Los Angeles, NRT 4501, CA 90033
USA



Regional Editor:

J.D. Miller (Biography
J.D. Miller

Dr. Miller received his Ph.D. in 1979 from the University of Texas, did a postdoc in dopamine electrophysiology at UT Southwestern until 1982, followed by a second postdoc in circadian neurobiology at UC Riverside and UC Davis until 1987. From 1982-1987 he also served as a NASA space shuttle project director. Dr. Miller was a research associate in the Stanford Biology Department from 1987-1994 and the Director of Neurochemistry in the Stanford-Upjohn Center for the Study of Sleep and Circadian Rhythms. He was a faculty member in the Department of Pharmacology, Texas Tech Health Sciences Center from 1994 until 2000.From 2000 to 2013 he was an associate professor in the Department of Cell and Neurobiology at the Keck School of Medicine at USC. In March 2013 he accepted a position as Chair of Pharmacology at the American University of the Caribbean School of Medicine where he continues to work.

)

American University of the Caribbean School of Medicine
Country of St. Maarten


Editorial Board Members:

C.N. Allen (Biography
C.N. Allen

Dr. Allen is a Professor at the Oregon Institute of Occupational Health Sciences and the Department of Behavioral Neuroscience at the Oregon Health & Science University. He received his Ph.D. in Pharmacology from University of Texas Southwestern Medical Center at Dallas. He has authored more than 75 manuscripts and six reviews. The research in his lab focuses on understanding how neurons in the hypothalamic suprachiasmatic nucleus (SCN) the master circadian oscillator generate circadian timing signals and entrain to the environmental light-dark cycle. We use single-cell electrophysiological recordings, long-term measurements of behavior, and long-term live cell imaging methods to study the signaling pathways in the neural network of SCN neurons and how those contribute to the synchronization of individual SCN oscillators.

)

Oregon Health & Science University
Portland, OR
USA

D. Bearss
University of Utah
UT
USA

C.H. Borchers (Biography
C.H. Borchers

Dr. Blanton obtained a doctorate (Ph.D.) in Biology/Biochemistry from the University of California, Santa Cruz, followed by postdoctoral training at Washington University School of Medicine, St. Louis, MO and at Harvard Medical School, Boston, MA. Currently Dr. Blanton is a Professor and Vice-Chair in the Department of Pharmacology and Neuroscience at Texas Tech University Health Sciences Center, Lubbock, TX. Dr. Blanton is also a Senior Associate Dean in the Graduate School of Biomedical Sciences and director of the MD/PhD Program and the Center for Membrane Protein Research. Dr. Blanton’s research focus is on the structure/function of ligand-gated ion channels, in particular neuronal nicotinic acetylcholine receptors (nAChRs).

)

University of Victoria
Victoria, BC
Canada

F. Carvalho
University of Porto
Porto
Portugal

R. J. Dinis-Oliveira (Biography
R. J. Dinis-Oliveira

Ricardo Jorge Dinis-Oliveira completed a PhD degree in Toxicology in the University of Porto. By Rector Dispatch awarded the European PhD. He holds 2 Post-Doc in Pharmacology and Toxicology and Habilitation (Aggregation) in Forensic Sciences by the Faculty of Medicine, University of Porto. He published more than 90 papers, 20 book chapters, edited three books and 4 patents. He is Director of the Course in Forensic Laboratorial Sciences, Course in Biomedical Sciences and of the Master in Forensic Sciences and Laboratory Techniques of University Institute of Health Sciences. He is the president elect of the Portuguese Association of Forensic Sciences.

)

University Institute of Health Sciences
University of Porto
Porto
Portugal

E. Elion (Biography
E. Elion

Dr Elion obtained a doctorate (Ph.D,) in Biochemistry from the Albert Einstein College of Medicine of Yeshiva University snd is a Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School of Harvard University.

)

Harvard University
Boston, MA
USA

A.A. Grace (Biography
A.A. Grace

Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. He has published more than 290 articles in the field of Neuropsychopharmacology.

)

University of Pittsburgh
Pittsburgh, PA
USA

C. Huang (Biography
C. Huang

Chaunshu Huang is a Professor of Department of Environmental Medicine and Biochemistry and Molecular Pharmacology and Urology, and Deputy Director of Nelson Institute of Environmental medicine, New York University School of Medicine. Dr. Huang published more than 280 research papers with total citation over 11,200. Chuanshu’s major research addresses fundamental questions concerning the responses of mammalian cells to environmental carcinogens at the levels of protein kinases, transcription factors and their target genes, as well as protein modification both in vitro and in vivo. His research also includes elucidation of tumor invasion and metastasis, as well as screening and identifying novel anti-cancer drugs and the molecular mechanisms underlying their anti-cancer effect.

)

New York University School of Medicine
New York, NY
USA

M.R. Kelley (Biography
M.R. Kelley

Dr. Kelley is the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Director, Program in Pediatric Molecular Oncology & Experimental Therapeutics, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center and the Associate Director for Basic Science at the IU Simon Cancer Center. Dr. Kelley has a PhD from LSU and postdoctorate at The Rockefeller University. He has published over 170 peer-reviewed articles, 30 reviews/book chapters and has 11 patents. He also edited both editions in DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications.

)

Indiana University Cancer Center
Indianapolis, IN
USA

R. Lewis (Biography
R. Lewis

As part of PhD studies at the University of Queensland with the late Bob Endean, he started research on polyether sodium channel activator toxins known as ciguatoxins, which are responsible for ciguatera fish poisoning. He then spent 10 years researching the problem at the Queensland Department of Primary Industries before moving back to The University of Queensland in 1995 to initiate research into the phamacology of conotoxins, small venom peptides produced by cone snails. This research led to the development of Xen2174 as a new class of non-competitive norepinephrine transporter inhibitors for the treatment of severe pain at Xenome Ltd, a company he co-founded. Professor Lewis’ current research interests include the origins and detection of ciguatoxins and the elucidation of the evolution and pharmacology of conopeptides, especially the discovery of novel classes of peptides peptides that may be useful for the treatment of pain. Presently he is Professor of Molecular Pharmacology, and inaugural Director of the IMB Centre for Pain Research in the Institute for Molecular Bioscience (IMB) at The University of Queensland, Australia.

)

The University of Queensland
St. Lucia, Queensland
Australia

G. Maksay (Biography
G. Maksay

Dr. Maksay received his Ph.D. in 1976 from Eötvös University of Sciences, Budapest, Hungary. His previous affiliations: Department of Molecular Pharmacology, Institute of Biomolecular Chemistry, Chemical Research Centre (1973-2011, from postdoc up to head of department); Research Group of Functional Pharmacology, Institute of Molecular Pharmacology and Institute of Organic Chemistry, Research Centre for Natural Sciences (senior research adviser, 2011-2015). He has retired as a research professor emeritus of the Hungarian Academy of Sciences. Research interests: receptorology; structure-activity relationships; ionotropic neurotransmitter receptors (GABAA, glycine, 5-HT3); allosteric modulation; recombinant receptors and voltage-clamp electrophysiology; receptor modeling; structural biology and symmetry violations of signalling complexes. He is Editorial Board member of the journal of the Hungarian Biochemical Society and of the World Journal of Pharmacology.

)

Research Centre for Natural Sciences Hungarian Academy of Sciences
Budapest
Hungary

H. Pelicano (Biography
H. Pelicano

Dr. Pelicano obtained a doctorate (Ph.D.) in Chemistry and biochemistry from the University of Montpellier II, France. Currently Dr. Pelicano is an instructor at MD Anderson cancer center in Houston. Dr. Pelicano’s research focuses on cancer metabolism, oxidative stress, anticancer agents, and novel therapeutic strategies. Dr. Pelicano has published more than 40 peer-reviewed research articles.

)

The University of Texas M. D. Anderson Cancer Center
Houston, TX
USA

J.R. Richardson
University of Medicine and Dentistry of New Jersey
NJ
USA

A. Schousboe (Biography
A. Schousboe

Arne Schousboe obtained his M.Sc. in biochemistry from The University of Copenhagen in 1968 at a time where an M. Sc. was considered equivalent to a Ph.D. He subsequently (1978) earned his Doctor of Science (D. Sc.) degree also from University of Copenhagen. In 1990 he moved to the Royal Danish School of Pharmacy, Copenhagen as a Full Professor of biochemistry. He has served as the Department Chair from 2005 to 2010 and is now part time Professor of Neuropharmacology in Department of Drug Design and Pharmacology at University of Copenhagen. He has published over 550 papers on these and related topics.

)

University of Copenhagen
Copenhagen
Denmark

J. Sprouse
Consulting LLC
Stonington, CT
USA

D.S. Tan (Biography
D.S. Tan

Derek S. Tan received his BS in Chemistry from Stanford in 1995, with Prof. Dale G. Drueckhammer, and his PhD in Chemistry from Harvard in 2000, with Prof. Stuart L. Schreiber. After postdoctoral training with Prof. Samuel J. Danishefsky at Memorial Sloan Kettering Cancer Center, he began his independent career at MSK in 2002. He is currently a tenured Member and Chairman of the Chemical Biology Program at MSK, a Tri-Institutional Professor at Rockefeller University and Weill Cornell Medicine, and Director of the Tri-Institutional PhD Program in Chemical Biology. His research focuses on diversity-oriented synthesis and rational drug design.

)

Memorial Sloan-Kettering Cancer Center
New York, NY
USA

D. Xiao (Biography
D. Xiao

Dr. DaLiao Xiao obtained a Ph.D. degree in Pharmacology from Loma Linda University School of Medicine, California. Dr. Xiao is an associate professor in the Center for Perinatal Biology, Loma Linda University, California, USA. Dr. Xiao’s research is mainly focusing on the fetal programming of cardiovascular system in response to in utero adverse environmental exposure. He and His research group try to understanding of the epigenetic mechanism and identify the epigenetic biomarkers during early life that have diagnostic value to predict the consequences of in utero adverse environmental exposure induced cardiovascular disease in adulthood. He has published more than 70 peer-reviewed scientific publications. His research projects are constantly supported by NIH and California State grants.

)

Loma Linda University School of Medicine
Loma Linda, CA 92350
USA

W. Zhu
Chinese Academy of Sciences
Shanghai
China

M. Attar
Allergan Inc.
Irvine, CA
USA

M.-A. Bjornsti
The University of Alabama at Birmingham
Birmingham, AL
USA

T.D. Bradshaw
School of Pharmacy, University of Nottingham
Nottingham
UK

S.A. Chow
University of California Los Angeles
Los Angeles, CA
USA

C. Dive
The University of Manchester
Manchester
UK

D.C. German (Biography
D.C. German

Dr. Dwight German received his Ph.D. training in neuroscience at the University of Oklahoma Health Sciences Center and went on to do post-doctoral work in the Department of Physiology & Biophysics and the Regional Primate Research Center at the University of Washington. He is currently a Professor in the Department of Psychiatry at the University of Texas Southwestern Medical Center. His research focuses on neurodegenerative and neurodevelopmental disorders using both post-mortem human tissues and animal models. His research also focuses on developing blood biomarkers for neurodegenerative/neurodevelopmental disorders.

)

University of Texas Southwestern Medical Center
Dallas, TX
USA

R. Greene
University of Texas Southwestern
Dallas, TX
USA

P. Huang
The University of Texas MD Anderson Cancer Center
Houston, TX
USA

M.J. Kuhar (Biography
M.J. Kuhar

Michael Kuhar has more than 40 years experience studying drugs and the brain. He has over 400 research publications, a number of patents and books, and has received many awards and prizes for his work. He has trained more than 60 younger scientists who have important positions around the world in academia, government and industry. Over his career, he has been Professor at Johns Hopkins, at the National Institutes of Health, and is currently at Emory. His website is at: http://www.michaeljkuhar.com/

)

Emory University
Atlanta, GA
USA

Y.-Q Long
Chinese Academy of Sciences
Shanghai
China

J.L. Nitiss
St. Jude Children's Research Hospital
Memphis, TN
USA

C. Plasencia (Biography
C. Plasencia

Dr. Plasencia obtained a doctorate (Ph.D.) in Medicine and surgery from the University Autonoma of Barcelona (Barcelona, Spain). Dr. Plasencia also holds an Executive Masters in Biotechnology from Genoma España and is currently finalizing the Executive Master in Business Administration from EAE business school (Barcelona). Currently Dr. Plasencia is co-founder and chief executive officer of the small biotech Applied Research using Omic Sciences (Aromics S.L.) and co-founder and chairman of the board of Aesis Therapeutics (Italy) and Acceleromics (Spain). All three biopharmaceutical companies are devoted to the development of novel antitumor and antiviral agents. She has scientific publications in international journals and currently acts as European expert for European Commision R&D programs.

)

(Applied Research using OMIC Sciences S.L.
Barcelona
Spain

A. Rodríguez (Biography
A. Rodríguez

My research interest was focused on new therapeutics strategies in cancer treatment. I studied Biochemistry at University of Basque Country (1992 – 1997) and obtained my PhD (1998 - 2002) in the Spanish National Research Council (IIB-CSIC). I was a junior scientist at the Department of R&D at Pharmamar Inc. (2003 - 2004), and at University of California Los Angeles (UCLA) (2005-2008). In 2009, I joined to DKFZ (German Cancer Research Center) in the division “Systems Biology of Signal Transduction”, as a project manager for LungSys consortium (2009-2015). Currently I am employed by German Center for Lung Research (DZL), in the multidisciplinary group of Lung Carcinoma.

)

German Cancer Research Center (DKFZ)
Heidelberg
Germany

R.-G Shao
Chinese Academy of Medical Sciences
Beijing
China

M.C. Stern
University of Southern California
Los Angeles, CA
USA

A.W. Tank
University of Rochester Medical Center
Rochester, NY
USA

N. Zhou
Zhejiang University
Hangzhou
China

P. Balakumar (Biography
P. Balakumar

Dr. Pitchai Balakumar has been working as Senior Associate Professor and Head of Pharmacology Unit at the Faculty of Pharmacy, AIMST University, Malaysia. Dr. Balakumar obtained M.Pharm and Ph.D degrees in Pharmacology from Punjabi University, Patiala, India. He has a vast teaching, research and editorial experience in the field of Cardiovascular Sciences, and trained several graduates. Dr. Balakumar published around 100 scientific papers in the areas of Cardiovascular, Diabetic and Renal Pharmacology. His papers have been cited for around 1600 times (SCOPUS), and his ‘H Index’ is 25 (SCOPUS). Dr. Balakumar received “Naranjan S. Dhalla Award” from the International Society of Heart Research (ISHR) and International Academy of Cardiovascular Sciences (IACS) in 2007. Along with Dr. Jagadeesh and Dr. Khin of US FDA, Dr. Balakumar has edited a reference book titled ‘Pathophysiology and Pharmacotherapy of Cardiovascular Disease’ published by the Springer in 2015.

)

Faculty of Pharmacy
AIMST University
Kedah
Malaysia

M.P. Blanton (Biography
M.P. Blanton

Dr. Blanton obtained a doctorate (Ph.D.) in Biology/Biochemistry from the University of California, Santa Cruz, followed by postdoctoral training at Washington University School of Medicine, St. Louis, MO and at Harvard Medical School, Boston, MA. Currently Dr. Blanton is a Professor and Vice-Chair in the Department of Pharmacology and Neuroscience at Texas Tech University Health Sciences Center, Lubbock, TX. Dr. Blanton is also a Senior Associate Dean in the Graduate School of Biomedical Sciences and director of the MD/PhD Program and the Center for Membrane Protein Research. Dr. Blanton’s research focus is on the structure/function of ligand-gated ion channels, in particular neuronal nicotinic acetylcholine receptors (nAChRs).

)

Texas Tech University Health Sciences Center
Lubbock, TX
USA

J.K. Buolamwini
University of Tennessee Health Science Center
Memphis, TN
USA

O. Civelli (Biography
O. Civelli

Dr. Civelli is Professor and Chair of the Department of Pharmacology at University of California, Irvine. He holds the Eric L and Lila D Nelson Chair of Neuropharmacology. Previously he was vice president at F. Hoffmann-La Roche, Basel. He is a recognized leader in the field of neuropsychopharmacology. He was the first to clone the D2 dopamine receptor and discovered the diversity of the dopamine receptors, in particular the D4 receptor. He spearheaded reverse pharmacology and used it to discover the first new neuropeptide identified by this approach, nociceptin/orphanin FQ and later neuropeptide S. He discovered the receptors for melanin concentrating hormone and for urotensin II. His primary interest is the study of neuropsychiatric disorders, in particular schizophrenia. He has authored more than 200 manuscripts and holds 30 patents.

)

University of California Irvine
Irvine, CA
USA

S.T. Eblen (Biography
S.T. Eblen

Scott T. Eblen, PhD, earned a BS in Biology from the University of Kentucky and a PhD from Vanderbilt University, performing his dissertation research both at Vanderbilt and the Mayo Clinic. He did postdoctoral work at the University of Virginia in the area of signal transduction by protein kinases. He is currently an Associate Professor of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina in Charleston, SC. His lab studies signal transduction by protein kinases, E3 ubiquitin ligases, and mRNA splicing in the context of cancer and molecular mechanisms of drug resistance.

)

Medical University of South Carolina
Charleston, SC
USA

D.A. Gewirtz (Biography
D.A. Gewirtz

The research in my laboratory for the past 30 years has been directed towards the areas of experimental chemotherapy and radiotherapy in cancer, with a primary focus on breast cancer and lung cancer. Work has been largely focused on sensitization of lung cancer and breast cancer to radiotherapy and chemotherapy. These efforts have also served to define autophagy and senescence (rather than apoptosis) as primary responses to both chemotherapy and radiotherapy in solid tumor cell models. We have established the existence of cytostatic and cytotoxic functions of autophagy in lung cancer cells and breast cancer cells while recent work has also identified a non-protective form of autophagy that is critical to understanding why efforts towards chemosensitization and radiosensitization via autophagy inhibition may prove to be particularly challenging in the absence of appropriate predictive biomarkers. Current work is focused on approaches for establishing the reversibility of senescence both in cell culture and tumor bearing animal models, with the longer term goal of understanding the role of senescence in sensitivity (or refractoriness) to therapy in breast and lung cancer.

)

Virginia Commonwealth University
Richmond, VA
USA

Maria Gulinello
Albert Einstein College of Medicine of Yeshiva University
New York, NY
USA

N. Jing
Baylor College of Medicine
Houston, TX
USA

M. J. Legato
Columbia University
New York, NY
USA

T.W. Lovenberg
Johnson & Johnson-Pharmaceutical R&D
San Diego, CA
USA

P.F. Oliveira
University of Porto
Porto
Portugal

P. Pourquier (Biography
P. Pourquier

Dr Philippe Pourquier obtained a doctorate (Ph.D.) in Biochemistry and Molecular Biology from the University of Bordeaux, France. Dr Pourquier also holds a Pharmacy Doctorate from the same University. Dr Pourquier is currently a Research Director at the french National Institute of Health and Medical Research (INSERM) in the research unit U1194 in Montpellier, France. Dr Pourquier acquired a solid experience in the field of drug resistance to anticancer agents, in particular DNA topoisomerases’ inhibitors and has published more than 60 papers in this field. He is developing basic and translational research programs to identify alternative therapies for the treatment of castration-resistant prostate cancers.

)

Institute of Cancer Research in Montpellier
Montpellier
France

M. Schmidt
University of Groningen
Groningen
The Netherlands

M.S. Sheikh
State University of New York
Syracuse, NY
USA

A. Sugawara
Tohoku University Graduate School of Medicine
Aoba-ku, Sendai
Japan

X. Wang
Merck Research Laboratories
Kenilworth, NJ 07033
USA

Q.-Y. Zhou (Biography
Q.-Y. Zhou

Dr. Naiming Zhou received his doctoral degree in molecular biology from Zhejiang Agricultural University in 1993. His postdoctoral work was done at KU Leuven, Belgium, and at Thomas Jefferson University, Philadelphia, respectively. In 2002, he joined Incyte Corporation, Delaware, where he was involved in drug discovery projects. Afterward, he returned to the Zhejiang University where he has been appointed Professor of Biochemistry and Molecular Biology in 2006. Dr. Zhou has published more than 60 peer reviewed SCI papers and awarded 5 patents.

)

University of California
Irvine, CA
USA


Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science